{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:12:19Z","timestamp":1760278339290,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,12,12]],"date-time":"2003-12-12T00:00:00Z","timestamp":1071187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high\u2010risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA) reduced the incidence of probable\/proven fungal infections in this group of patients, and compare the results with those of a historic control group treated with fluconazole plus itraconazole capsules (F+I).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with AML and high\u2010risk MDS who underwent induction chemotherapy received 200 mg of i.v. itraconazole over 60 minutes every 12 hours during the first 2 days followed by 200 mg given i.v. once daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>One hundred patients were enrolled, 96 of whom were evaluable. Approximately 48% of the patients in the group of patients treated with IV ITRA as well as in the F+I group completed prophylaxis. Nine patients (9%) in the study group developed either proven\/probable fungal infections (Candida <jats:italic>glabrata<\/jats:italic> in 5 patients, C. <jats:italic>tropicalis<\/jats:italic> in 1 patient, C <jats:italic>krusei<\/jats:italic> in 1 patient, and F<jats:italic>usarium<\/jats:italic> in 2 patients) compared with 3 patients (4%) with proven fungal infection in the historic control group (C. <jats:italic>tropicalis<\/jats:italic> in 1 patient and A<jats:italic>spergillus<\/jats:italic> in 2 patients). There were no significant differences noted between the two groups with regard to the percentage of patients who developed proven\/probable or possible fungal infection as well as with regard to survival. These results also were obtained after adjusting for relevant prognostic factors (creatinine and bilirubin). The most common toxicity encountered with the use of IV ITRA was NCI Grade 3\u20104 hyperbilirubinemia (6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Despite its theoretic advantages, the authors found no evidence that IV ITRA is superior to itraconazole capsules, at least when the latter is combined with fluconazole. Cancer 2004. \u00a9 2003 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11930","type":"journal-article","created":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T04:00:50Z","timestamp":1074744050000},"page":"568-573","source":"Crossref","is-referenced-by-count":17,"title":["Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high\u2010risk myelodysplastic syndrome undergoing induction chemotherapy"],"prefix":"10.1002","volume":"100","author":[{"given":"Gloria N.","family":"Mattiuzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. Nebiyou","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard J.","family":"Leitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Raad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V60.2.309.309","article-title":"Causes of initial remission failure in patients with acute myelogenous leukemia","volume":"60","author":"Estey E","year":"1982","journal-title":"Blood."},{"key":"e_1_2_5_3_2","first-page":"600","article-title":"Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"10","author":"Anderlini P","year":"1996","journal-title":"Leukemia."},{"key":"e_1_2_5_4_2","first-page":"11a","article-title":"Causes of pneumonia (PN) in patients (PTS) with acute myelogenous leukemia (AML) or\u2013 myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC)","volume":"96","author":"Mattiuzzi G","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.981-985.2001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04465.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.5.376"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1887-1893.2000"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/515129"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.97"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01465.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11094"},{"key":"e_1_2_5_14_2","first-page":"257","article-title":"Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia","volume":"3","author":"Estey E","year":"1989","journal-title":"Leukemia."},{"key":"e_1_2_5_15_2","first-page":"2591","article-title":"Prognostic factors in cancer clinical trials","volume":"3","author":"Estey E","year":"1997","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_16_2","unstructured":"National Cancer Institute common toxicity criteria\u2013version 1. Available from URL:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/toxicity.cfmhttp:\/\/ctep.cancer.gov\/reporting\/ctc.html[accessed April2000]."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11930","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:39:54Z","timestamp":1760276394000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,20]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1002\/cncr.11930"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11930","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2004,1,20]]}}}